Iovance Biotherapeutics Showcases TIL Therapy Advances and Melanoma Treatment Outcomes in New Corporate Presentation

Reuters01-09

<a href="https://laohu8.com/S/IOVA">Iovance Biotherapeutics</a> Showcases TIL Therapy Advances and Melanoma Treatment Outcomes in New Corporate Presentation

Iovance Biotherapeutics Inc. has released a corporate presentation detailing recent advancements and commercial progress in tumor-infiltrating lymphocyte $(TIL)$ therapy for cancer patients. The company reported that over 1,000 patients have been treated with its commercial and clinical TIL products, with more than 85 authorized treatment centers as of the end of 2025. Financial highlights include anticipated fiscal year 2025 revenue in the range of $250 million to $300 million and a gross margin of 43% in the third quarter of 2025. Iovance’s product Amtagvi®, indicated for previously treated advanced melanoma, demonstrated an objective response rate of 31.4%, a median duration of response of 36.5 months, and a five-year overall survival rate of 19.7% based on a pooled analysis. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602375871?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602375871","market":"nz","top_or_hot":-1,"title":"Iovance Biotherapeutics Showcases TIL Therapy Advances and Melanoma Treatment Outcomes in New Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics</a> Showcases TIL Therapy Advances and Melanoma Treatment Outcomes in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Iovance Biotherapeutics Inc. has released a corporate presentation detailing recent advancements and commercial progress in tumor-infiltrating lymphocyte <a href=\"https://laohu8.com/S/TIL\">$(TIL)$</a> therapy for cancer patients. The company reported that over 1,000 patients have been treated with its commercial and clinical TIL products, with more than 85 authorized treatment centers as of the end of 2025. Financial highlights include anticipated fiscal year 2025 revenue in the range of $250 million to $300 million and a gross margin of 43% in the third quarter of 2025. Iovance’s product Amtagvi®, indicated for previously treated advanced melanoma, demonstrated an objective response rate of 31.4%, a median duration of response of 36.5 months, and a five-year overall survival rate of 19.7% based on a pooled analysis. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance Biotherapeutics Showcases TIL Therapy Advances and Melanoma Treatment Outcomes in New Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance Biotherapeutics Showcases TIL Therapy Advances and Melanoma Treatment Outcomes in New Corporate Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-09 20:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics</a> Showcases TIL Therapy Advances and Melanoma Treatment Outcomes in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Iovance Biotherapeutics Inc. has released a corporate presentation detailing recent advancements and commercial progress in tumor-infiltrating lymphocyte <a href=\"https://laohu8.com/S/TIL\">$(TIL)$</a> therapy for cancer patients. The company reported that over 1,000 patients have been treated with its commercial and clinical TIL products, with more than 85 authorized treatment centers as of the end of 2025. Financial highlights include anticipated fiscal year 2025 revenue in the range of $250 million to $300 million and a gross margin of 43% in the third quarter of 2025. Iovance’s product Amtagvi®, indicated for previously treated advanced melanoma, demonstrated an objective response rate of 31.4%, a median duration of response of 36.5 months, and a five-year overall survival rate of 19.7% based on a pooled analysis. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL9kRnY7:1","article_id":"2602375871","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602375871","pubTimestamp":1767962470,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Iovance Biotherapeutics Inc. has released a corporate presentation detailing recent advancements and commercial progress in tumor-infiltrating lymphocyte  therapy for cancer patients. The company reported that over 1,000 patients have been treated with its commercial and clinical TIL products, with more than 85 authorized treatment centers as of the end of 2025. Financial highlights include anticipated fiscal year 2025 revenue in the range of $250 million to $300 million and a gross margin of 43% in the third quarter of 2025. Iovance’s product Amtagvi, indicated for previously treated advanced melanoma, demonstrated an objective response rate of 31.4%, a median duration of response of 36.5 months, and a five-year overall survival rate of 19.7% based on a pooled analysis. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"Iovance Biotherapeutics在新的公司演示中展示了TIL治疗进展和黑色素瘤治疗结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":0.9},"content_text":"Iovance Biotherapeutics Showcases TIL Therapy Advances and Melanoma Treatment Outcomes in New Corporate Presentation\n    \n\n        Iovance Biotherapeutics Inc. has released a corporate presentation detailing recent advancements and commercial progress in tumor-infiltrating lymphocyte $(TIL)$ therapy for cancer patients. The company reported that over 1,000 patients have been treated with its commercial and clinical TIL products, with more than 85 authorized treatment centers as of the end of 2025. Financial highlights include anticipated fiscal year 2025 revenue in the range of $250 million to $300 million and a gross margin of 43% in the third quarter of 2025. Iovance’s product Amtagvi®, indicated for previously treated advanced melanoma, demonstrated an objective response rate of 31.4%, a median duration of response of 36.5 months, and a five-year overall survival rate of 19.7% based on a pooled analysis. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602375871","isCrawlerRequest":true}